This SME coordinated and dominated STREP will investigate new malaria vaccine candidates with the objective of taking at least one through to GLP pilot scale up. The most promising candidates will undergo in vitro and in vivo testing, lead optimisation, safety and toxicology testing according to GLP standards. The combination of efforts presented in this STREP will generate several recombinant measles viruses expressing a variety of malaria antigens based primarily upon MSP-1 and secondarily on AMA-1.
In order to maximise on the capabilities of the SMEs and two of the leading European malaria research institutes, this STREP will concentrate on six workpackages: WP1 Project Management; WP2 Development of transgenic humanised mice, Delivery of malaria antigen coding sequences; WP3 Delivery of block 2 malaria antigens; WP4 Hybrid malaria antigen development, Primate challenge studies; WP5 Development of MeVs expressing multiple blood stage malaria antigens; WP6 Validation and Biosafety evaluation of candidate vaccines.
The timeframe and budget allocated directly reflect the requirements for such a proposal, including contingency plans. In addition, this STREP application, coordinated by EtnaVax, will compliment the detailed work laid out in other larg er European research projects and proposals. As such it forms an essential stepping-stone in the trans-European malaria vaccine initiative.
Call for proposal
See other projects for this call